BiotechTube
Home/Boehringer Ingelheim/Michael Schmelmer
MS

Michael Schmelmer

Member of the Board of Managing Directors

Boehringer Ingelheim

Therapeutic Areas

Cardio-Renal-MetabolismImmunologyOncologyMental HealthAnimal Health

Boehringer Ingelheim Pipeline

DrugIndicationPhase
Empagliflozin (Jardiance)Heart Failure, Chronic Kidney DiseasePhase 3 / Marketed
Spesolimab (Spevigo)Generalized Pustular Psoriasis (GPP)Marketed
BI 1701963KRAS-mutant solid tumorsPhase 1
Novel Immunology BiologicsUlcerative Colitis, Crohn's DiseasePhase 2

Leadership Team at Boehringer Ingelheim

HV
Hubertus von Baumbach
Chairman of the Board of Managing Directors
JS
Jean Scheftsik de Szolnok
Member of the Board of Managing Directors
View full Boehringer Ingelheim profile